China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing

Volume/Pricing Trade-Off

 
• By Dexter Jie Yan
  
2022 round NRDL price talk
36% more novel drugs win national reimbursement in latest annual China negotiations • Source: Shutterstock

More from China

More from Focus On Asia